Navigation Links
Chiltern Announces Collaboration With Dr Nawab Qizilbash
Date:12/17/2009

LONDON, Dec. 17 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global clinical research organization (CRO) providing clinical development and staffing services in Europe, the Americas and Asia, is pleased to announce our collaboration with Dr Nawab Qizilbash of OXON Epidemiology.

Dr Nawab Qizilbash, MBChB BSc MRCP (UK) MSc Phil (Oxon) is the Director of OXON Epidemiology Ltd. He served as Director of Epidemiology and Evidence-based Medicine at GlaxoSmithKline. Formerly an Honorary Consultant Physician/Senior Research Fellow at Radcliffe Infirmary, Oxford University, Nawab trained under Professor Sir Richard Peto F.R.S. in epidemiology, Phase IV trials and meta-analysis. He also collaborates with Professor Stephen Evans in academic research on statistical signal detection. Dr Qizilbash has authored 5 publications in the Lancet, 1 in the Journal of the American Medical Association and 1 in the British Medical Journal, among others. He founded the Cochrane Dementia Group and is chief editor of an international textbook on clinical dementia.

Jane Turner, MRPharmS, Chiltern's Late Phase Director, Europe, stated, "We are delighted to announce the alliance between Chiltern Late Phase and Dr Nawab Qizilbash and his company, OXON Epidemiology Ltd. OXON is a niche consultancy company that specializes in 'real world data': epidemiology, risk management and health economics. This partnership will allow Chiltern to provide epidemiology and outcomes research expertise in conjunction with flexible and bespoke late phase study solutions to our sponsors. Steve Albrecht, Global head of Chiltern Late Phase, added, "We are excited about this ongoing collaboration which significantly strengthens Chiltern's global service offering in epidemiology, pharmacoeconomics and risk management.

Dr Qizilbash commented, "OXON is delighted to be collaborating with Chiltern Late Phase. The combination provides scientific strength with breadth and global reach to late phase, allowing for strategic consulting, planning and implementation of: observational studies, risk management, health economics and Phase IV trials."

Company profile

About Chiltern:

Established in 1982, Chiltern is a leading global clinical Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad range of therapeutic areas for a wide variety of clients. Chiltern has conducted trials in more than 40 countries and employs 1,400 people in 29 countries. Chiltern provides Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions services. Further information: www.chiltern.com.


    For More Information:

    Natalie Chong, Chiltern International Ltd.
    171 Bath Road
    Slough, Berkshire SL1 4AA, UK
    Tel:  44 (0) 1753 512 000
    Email: natalie.chong@chiltern.com

    Sue Ojanen, Chiltern International Inc.
    1241 Volunteer Parkway
    Bristol, TN 37620, USA
    Tel:  1 (423) 968 9533
    Email: sue.ojanen@chiltern.com

SOURCE Chiltern


'/>"/>
SOURCE Chiltern
Copyright©2009 PR Newswire.
All rights reserved

Related biology news :

1. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
2. LaserCard Corporation Announces Expansion of Middle East Project
3. BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution
4. Balzan Foundation announces 2007 winners
5. The American Society of Plant Biologists announces 2007 awards
6. ASPB announces Summer Undergraduate Research Fellowship 2007 recipients
7. NIST announces 56 new awards for innovative technology research and development
8. Titanium Group Announces Contract With Haitong Securities
9. Measurement Specialties, Inc. Announces Impact of German Business Tax Reform 2008 Resulting in Lower Combined German Tax Rate - Impacts 2Q08 Reported Financial Results
10. FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change
11. HGS announces positive Phase 2 LymphoStat-B at ACR meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2016)... "The biometric system market ... The biometric system market is in the growth stage ... future. The biometric system market is expected to be ... CAGR of 16.79% between 2016 and 2022. Government initiative ... in smartphones, rising use of biometric technology in financial ...
(Date:11/21/2016)... , Nov. 21, 2016   Neurotechnology , ... recognition technologies, today announced that the MegaMatcher On ... was submitted for the NIST Minutiae Interoperability ... all the mandatory steps of the evaluation protocol. ... a continuing test of fingerprint templates used to ...
(Date:11/16/2016)... 2016 Sensory Inc ., a ... for consumer electronics, and VeriTran , a ... industry, today announced a global partnership that will ... authenticate users of mobile banking and mobile payments ... software which requires no specialized biometric scanners, yet ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... ... 2016 , ... Robots will storm the Prudential Center in Boston, MA during ... which is held on the United Nations International Day of Persons with Disabilities, will ... workplace. Suitable Technologies is partnering with NTI to showcase how technology can help individuals ...
(Date:11/30/2016)... ... November 30, 2016 , ... BEI Kimco, a brand ... a flexure design that ensures high alignment accuracy by preventing unwanted shaft rotation. ... suited where extreme precision is required, such as in medical equipment, laboratory instrumentation, ...
(Date:11/30/2016)... BOCA RATON, Fla. , Nov. 30, 2016 /PRNewswire/ ... immunological biotherapeutic products, is pleased to announce the addition ... 1st Avenue Kearney, Nebraska . The ... for business on November 29th, 2016 and brings the ... Ileana Carlisle , BPC,s Chief ...
(Date:11/30/2016)... BEIJING , Nov. 30, 2016 Novogene ... services and solutions with cutting edge next-generation sequencing (NGS) ... a USD $75 Million [515 Million RMB] B round ... Capital Management ( Shenzhen ) Co., Ltd. ... Innovation") and Shanghai Sigma Square Investment Center LP ("Sigma ...
Breaking Biology Technology: